Emerging drugs for the treatment of adult MOG-IgG-associated diseases

Figures & data

Table 1. Most relevant case series including adult patients with MOG-IgG associated diseases

Drug	Author	Study design	Number of adults treated	Follow up in years (median)	ARR post treatment (range or SD) or relapse rate reduction
Prednisone	Ramanathan et al^[12]	Retrospective	20*	5	0 (0–1.57)
Azathioprine	Jarius et al^[25]	Retrospective	18	6.25	0.99 (0–6)
	Chen et al^[17]	Retrospective	14	1.8	0.43 (0–3.4)
	Cobo-calvo et al^[20]	Retrospective	19	2.1	0.43 (0.79)
Mycophenolate mofetil	Cobo-Calvo et al^[20]	Retrospective	12	1.7	0.23 (0.60)
	Chen et al^[17]	Retrospective	15	1.1	0.4 (0–5.2)
	Li et al^[21]	Retrospective	33	1.3	Reduced the relapse risk (HR = 0.11)
Rituximab	Cobo-Calvo et al^[20]	Retrospective	30	1.7	0.43 (0.89)
	Chen et al^[17]	Retrospective	30	1.2	0.59 (0–6.8)
	Whittam et al^[23]	Retrospective	71	1.1	0 (0.00–1.25)
IVIG	Chen et al^[17]	Retrospective	5	1.2	0.1 (0–0.2)

*It is not assessed how many adult patients were treated with steroids.

Ramanathan S, Mohammad S, Tantsis E, et al., Australasian and New Zealand MOG Study Group. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):127–137.

 PubMed Web of Science ®Google Scholar

Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016Sep27;13(1):280.

 PubMed Web of Science ®Google Scholar

Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020 Jul 14;95(2):e111–e120.

 PubMed Web of Science ®Google Scholar

Cobo-Calvo A, Sepúlveda M, Rollot F, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation. 2019 Jul 2;16(1):134.

 PubMedGoogle Scholar

Li S, Ren H, Xu Y, et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study. Neurol Neuroimmunol Neuroinflamm. 2020 Mar 13;7(3):e705.

 PubMed Web of Science ®Google Scholar

Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Scler Relat Disord. 2020 Sep;44:102251.

 PubMed Web of Science ®Google Scholar